What's new? Log in Free sign up

Table search / Charles River Laboratories International, Inc. / "Employee"

7 results

Newest first Best match first

CRL Charles River Laboratories International, Inc.

Quarterly report

Redeemable Noncontrolling Interests	Common Stock									Additional Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Treasury Stock			Total Charles River Laboratories, Inc. Equity			Noncontrolling Interest			Total Equity
Shares			Amount			Shares			Amount			December 31, 2022			$	42,427	50,944	$	509	$	1,804,940	$	1,432,901	$	(262,057)	—	$	—	$	2,976,293	$	4,785	$	2,981,078	Net income	322		—	—	—	103,131	—	—	—	103,131	501	103,632	Other comprehensive income (loss), net of tax	186		—	—	—	—	22,933	—	—	22,933	—	22,933	Issuance of stock under employee compensation plans	—		316	3	11,789	—	—	—	—	11,792	—	11,792	Purchase of treasury shares	—		—	—	—	—	—	78	(19,012)	(19,012)	—	(19,012)	Stock-based compensation	—		—	—	13,460	—	—	—	—	13,460	—	13,460	April 1, 2023	42,935		51,260	512	1,830,189	1,536,032	(239,124)	78	(19,012)	3,108,597	5,286	3,113,883	Net income	1,857		—	—	—	97,020	—	—	—	97,020	566	97,586	Other comprehensive income (loss), net of tax	(2,345)		—	—	—	—	30,855	—	—	30,855	—	30,855	Issuance of stock under employee compensation plans	—		110	1	3,926	—	—	—	—	3,927	—	3,927	Purchase of treasury shares	—		—	—	—	—	—	26	(4,966)	(4,966)	—	(4,966)	Stock-based compensation	—		—	—	16,270	—	—	—	—	16,270	—	16,270	July 1, 2023	42,447		51,370	513	1,850,385	1,633,052	(208,269)	104	(23,978)	3,251,703	5,852	3,257,555	Net income	71		—	—	—	87,389	—	—	—	87,389	561	87,950	Other comprehensive income (loss), net of tax	(192)		—	—	—	—	(59,797)	—	—	(59,797)	—	(59,797)	Dividends to noncontrolling interest	(2,378)		—	—	—	—	—	—	—	—	(1,645)	(1,645)	Issuance of stock under employee compensation plans	—		30	1	3,938	—	—	—	—	3,939	—	3,939	Purchase of treasury shares	—		—	—	—	—	—	—	(38)	(38)	—	(38)	Stock-based compensation	—		—	—	22,797	—	—	—	—	22,797	—	22,797	September 30, 2023	$	39,948	51,400	$	514	$	1,877,120	$	1,720,441	$	(268,066)	104	$	(24,016)	$	3,305,993	$	4,768	$	3,310,761	See Notes to Unaudited Condensed Consolidated Financial Statements.

6 Nov 24

9:16am

CRL Charles River Laboratories International, Inc.

Quarterly report

Redeemable Noncontrolling Interests	Common Stock									Additional Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Treasury Stock			Total Charles River Laboratories, Inc. Equity			Noncontrolling Interest			Total Equity
Shares			Amount			Shares			Amount			December 30, 2023			$	56,722	51,338	$	513	$	1,905,578	$	1,887,218	$	(196,427)	—	$	—	$	3,596,882	$	5,394	$	3,602,276	Net income	1,201		—	—	—	72,960	—	—	—	72,960	321	73,281	Other comprehensive (loss), net of tax	(2,763)		—	—	—	—	(53,492)	—	—	(53,492)	—	(53,492)	Adjustment of redeemable noncontrolling interests to redemption value	4,807		—	—	(4,406)	(401)	—	—	—	(4,807)	—	(4,807)	Dividends to noncontrolling interests	(2,192)		—	—	—	—	—	—	—	—	—	—	Issuance of stock under employee compensation plans	—		214	2	21,503	—	—	—	—	21,505	—	21,505	Purchase of treasury shares	—		—	—	—	—	—	42	(9,351)	(9,351)	—	(9,351)	Stock-based compensation	—		—	—	16,738	—	—	—	—	16,738	—	16,738	March 30, 2024	57,775		51,552	515	1,939,413	1,959,777	(249,919)	42	(9,351)	3,640,435	5,715	3,646,150	Net income	(332)		—	—	—	94,081	—	—	—	94,081	512	94,593	Other comprehensive income (loss), net of tax	85		—	—	—	—	(19,790)	—	—	(19,790)	—	(19,790)	Adjustment of redeemable noncontrolling interest to redemption value	496		—	—	(195)	(301)	—	—	—	(496)	—	(496)	Dividends to noncontrolling interests	—		—	—	—	—	—	—	—	—	(1,938)	(1,938)	Purchase of remaining equity interest of other redeemable noncontrolling interest	(12,000)		—	—	—	—	—	—	—	—	—	—	Adjustment of purchase price of Noveprim redeemable noncontrolling interest	52		—	—	—	—	—	—	—	—	—	—	Issuance of stock under employee compensation plans	—		144	2	824	—	—	—	—	826	—	826	Purchase of treasury shares	—		—	—	—	—	—	41	(8,914)	(8,914)	—	(8,914)	Stock-based compensation	—		—	—	16,587	—	—	—	—	16,587	—	16,587	June 29, 2024	46,076		51,696	517	1,956,629	2,053,557	(269,709)	83	(18,265)	3,722,729	4,289	3,727,018	Net income	73		—	—	—	69,657	—	—	—	69,657	565	70,222	Other comprehensive (loss) income, net of tax	(876)		—	—	—	—	76,838	—	—	76,838	—	76,838	Adjustment of redeemable noncontrolling interest to redemption value	5,705		—	—	(5,326)	(379)	—	—	—	(5,705)	—	(5,705)	Dividends to noncontrolling interest	(10,388)		—	—	—	—	—	—	—	—	—	—	Issuance of stock under employee compensation plans	—		22	—	779	—	—	—	—	779	—	779	Purchase of treasury shares	—		—	—	—	—	—	501	(100,786)	(100,786)	—	(100,786)	Share repurchase excise tax	—		—	—	—	—	—	—	(570)	(570)	—	(570)	Stock-based compensation	—		—	—	19,331	—	—	—	—	19,331	—	19,331	September 28, 2024	$	40,590	51,718	$	517	$	1,971,413	$	2,122,835	$	(192,871)	584	$	(119,621)	$	3,782,273	$	4,854	$	3,787,127	See Notes to Unaudited Condensed Consolidated Financial Statements.

6 Nov 24

9:16am

CRL Charles River Laboratories International, Inc.

Quarterly report

Redeemable Noncontrolling Interests	Common Stock									Additional Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Treasury Stock			Total Charles River Laboratories, Inc. Equity			Noncontrolling Interest			Total Equity
Shares			Amount			Shares			Amount			December 31, 2022			$	42,427	50,944	$	509	$	1,804,940	$	1,432,901	$	(262,057)	—	$	—	$	2,976,293	$	4,785	$	2,981,078	Net income	322		—	—	—	103,131	—	—	—	103,131	501	103,632	Other comprehensive income, net of tax	186		—	—	—	—	22,933	—	—	22,933	—	22,933	Issuance of stock under employee compensation plans	—		316	3	11,789	—	—	—	—	11,792	—	11,792	Purchase of treasury shares	—		—	—	—	—	—	78	(19,012)	(19,012)	—	(19,012)	Stock-based compensation	—		—	—	13,460	—	—	—	—	13,460	—	13,460	April 1, 2023	42,935		51,260	512	1,830,189	1,536,032	(239,124)	78	(19,012)	3,108,597	5,286	3,113,883	Net income	1,857		—	—	—	97,020	—	—	—	97,020	566	97,586	Other comprehensive income, net of tax	(2,345)		—	—	—	—	30,855	—	—	30,855	—	30,855	Issuance of stock under employee compensation plans	—		110	1	3,926	—	—	—	—	3,927	—	3,927	Purchase of treasury shares	—		—	—	—	—	—	26	(4,966)	(4,966)	—	(4,966)	Stock-based compensation	—		—	—	16,270	—	—	—	—	16,270	—	16,270	July 1, 2023	$	42,447	51,370	$	513	$	1,850,385	$	1,633,052	$	(208,269)	104	$	(23,978)	$	3,251,703	$	5,852	$	3,257,555	See Notes to Unaudited Condensed Consolidated Financial Statements.

7 Aug 24

9:15am

CRL Charles River Laboratories International, Inc.

Quarterly report

Redeemable Noncontrolling Interests	Common Stock									Additional Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Treasury Stock			Total Charles River Laboratories, Inc. Equity			Noncontrolling Interest			Total Equity
Shares			Amount			Shares			Amount			December 30, 2023			$	56,722	51,338	$	513	$	1,905,578	$	1,887,218	$	(196,427)	—	$	—	$	3,596,882	$	5,394	$	3,602,276	Net income	1,201		—	—	—	72,960	—	—	—	72,960	321	73,281	Other comprehensive (loss), net of tax	(2,763)		—	—	—	—	(53,492)	—	—	(53,492)	—	(53,492)	Adjustment of redeemable noncontrolling interests to redemption value	4,807		—	—	(4,406)	(401)	—	—	—	(4,807)	—	(4,807)	Dividends to noncontrolling interests	(2,192)		—	—	—	—	—	—	—	—	—	—	Issuance of stock under employee compensation plans	—		214	2	21,503	—	—	—	—	21,505	—	21,505	Purchase of treasury shares	—		—	—	—	—	—	42	(9,351)	(9,351)	—	(9,351)	Stock-based compensation	—		—	—	16,738	—	—	—	—	16,738	—	16,738	March 30, 2024	57,775		51,552	515	1,939,413	1,959,777	(249,919)	42	(9,351)	3,640,435	5,715	3,646,150	Net income	(332)		—	—	—	94,081	—	—	—	94,081	512	94,593	Other comprehensive income (loss), net of tax	85		—	—	—	—	(19,790)	—	—	(19,790)	—	(19,790)	Adjustment of redeemable noncontrolling interest to redemption value	496		—	—	(195)	(301)	—	—	—	(496)	—	(496)	Dividends to noncontrolling interests	—		—	—	—	—	—	—	—	—	(1,938)	(1,938)	Purchase of remaining equity interest of other redeemable noncontrolling interest	(12,000)		—	—	—	—	—	—	—	—	—	—	Adjustment of purchase price of Noveprim redeemable noncontrolling interest	52		—	—	—	—	—	—	—	—	—	—	Issuance of stock under employee compensation plans	—		144	2	824	—	—	—	—	826	—	826	Purchase of treasury shares	—		—	—	—	—	—	41	(8,914)	(8,914)	—	(8,914)	Stock-based compensation	—		—	—	16,587	—	—	—	—	16,587	—	16,587	June 29, 2024	$	46,076	51,696	$	517	$	1,956,629	$	2,053,557	$	(269,709)	83	$	(18,265)	$	3,722,729	$	4,289	$	3,727,018	See Notes to Unaudited Condensed Consolidated Financial Statements.

7 Aug 24

9:15am

CRL Charles River Laboratories International, Inc.

Quarterly report

Redeemable Noncontrolling Interests	Common Stock									Additional Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Treasury Stock			Total Charles River Laboratories, Inc. Equity			Noncontrolling Interest			Total Equity
Shares			Amount			Shares			Amount			December 30, 2023			$	56,722	51,338	$	513	$	1,905,578	$	1,887,218	$	(196,427)	—	$	—	$	3,596,882	$	5,394	$	3,602,276	Net income	1,201		—	—	—	72,960	—	—	—	72,960	321	73,281	Other comprehensive (loss), net of tax	(2,763)		—	—	—	—	(53,492)	—	—	(53,492)	—	(53,492)	Adjustment of redeemable noncontrolling interests to redemption value	4,807		—	—	(4,406)	(401)	—	—	—	(4,807)	—	(4,807)	Dividends to noncontrolling interests	(2,192)		—	—	—	—	—	—	—	—	—	—	Issuance of stock under employee compensation plans	—		214	2	21,503	—	—	—	—	21,505	—	21,505	Purchase of treasury shares	—		—	—	—	—	—	42	(9,351)	(9,351)	—	(9,351)	Stock-based compensation	—		—	—	16,738	—	—	—	—	16,738	—	16,738	March 30, 2024	$	57,775	51,552	$	515	$	1,939,413	$	1,959,777	$	(249,919)	42	$	(9,351)	$	3,640,435	$	5,715	$	3,646,150	Redeemable Noncontrolling Interests	Common Stock									Additional Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Treasury Stock			Total Charles River Laboratories, Inc. Equity			Noncontrolling Interest			Total Equity
Shares			Amount			Shares			Amount			December 31, 2022			$	42,427	50,944	$	509	$	1,804,940	$	1,432,901	$	(262,057)	—	$	—	$	2,976,293	$	4,785	$	2,981,078	Net income	322		—	—	—	103,131	—	—	—	103,131	501	103,632	Other comprehensive income, net of tax	186		—	—	—	—	22,933	—	—	22,933	—	22,933	Adjustment of redeemable noncontrolling interest to redemption value	—		—	—	—	—	—	—	—	—	—	—	Issuance of stock under employee compensation plans	—		316	3	11,789	—	—	—	—	11,792	—	11,792	Purchase of treasury shares	—		—	—	—	—	—	78	(19,012)	(19,012)	—	(19,012)	Stock-based compensation	—		—	—	13,460	—	—	—	—	13,460	—	13,460	April 1, 2023	$	42,935	51,260	$	512	$	1,830,189	$	1,536,032	$	(239,124)	78	$	(19,012)	$	3,108,597	$	5,286	$	3,113,883	See Notes to Unaudited Condensed Consolidated Financial Statements.

9 May 24

9:17am

14 Feb 24

9:19am

hjgw2pp4pm7f9 yno

14 Feb 24

9:19am

Prev
1
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.